PuSH - Publication Server of Helmholtz Zentrum München

Bornstein, S.R. ; Voit-Bak, K.* ; Donate, T.* ; Rodionov, R.N.* ; Gainetdinov, R.R.* ; Tselmin, S.* ; Kanczkowski, W.* ; Müller, G.M.* ; Achleitner, M.* ; Wang, J.* ; Licinio, J.* ; Bauer, M.* ; Young, A.H.* ; Thuret, S.* ; Bechmann, N.* ; Straube, R.*

Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?

Mol. Psychiatry 27, 34-37 (2022)
Publ. Version/Full Text DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
As millions of patients have been infected by SARS-CoV-2 virus a vast number of individuals complain about continuing breathlessness and fatigue even months after the onset of the disease. This overwhelming phenomenon has not been well defined and has been called "post-COVID syndrome" or "long-COVID" [1]. There are striking similarities to myalgic encephalomyelitis also called chronic fatigue syndrome linked to a viral and autoimmune pathogenesis. In both disorders neurotransmitter receptor antibodies against ß-adrenergic and muscarinic receptors may play a key role. We found similar elevation of these autoantibodies in both patient groups. Extracorporeal apheresis using a special filter seems to be effective in reducing these antibodies in a significant way clearly improving the debilitating symptoms of patients with chronic fatigue syndrome. Therefore, such a form of neuropheresis may provide a promising therapeutic option for patients with post-COVID-19 syndrome. This method will also be effective when other hitherto unknown antibodies and inflammatory mediators are involved.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Covid-19; System
ISSN (print) / ISBN 1359-4184
e-ISSN 1476-5578
Quellenangaben Volume: 27, Issue: 1, Pages: 34-37 Article Number: , Supplement: ,
Publisher Nature Publishing Group
Publishing Place Campus, 4 Crinan St, London, N1 9xw, England
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)
Grants GWT-TUD GmbH
Deutsche Forschungsgemeinschaft (DFG) within the CRC/Transregio
Zentrum fur Apherese- und Hamofiltration am INUS Tagesklinikum
Alrex Alpha Ltd.